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Abstract 
Objective: Although low bone mineral density (BMD) is prevalent in HIV, changes in BMD 
over time remain unclear. We aimed to compare rates of, and factors associated with, BMD 
change between HIV-positive and HIV-negative subjects. 
Methods: In a prospective, 3-year cohort, HIV-positive and HIV-negative subjects provided 
annual demographic and clinical data, fasting bloods and dual x-ray absorptiometry (DXA). 
Using longitudinal mixed models we compared and determined predictors of rate of change 
in BMD.  
Results: Of 384 subjects (45.8% HIV-positive), 120 contributed two and 264 contributed 
three BMD measurements. Those with HIV were younger (median (IQR) 39 (34-46) vs 43 
(35-50) years; p=0.04), more often male (61% vs 46%; p=0.003) and less likely Caucasian 
(61% vs 82%; p<0.001). Although BMD was lower in those with HIV, BMD declined in 
both groups, with non-significant between-group difference in rate of BMD change over 
time. 
Within the HIV group, starting ART within 3 months of enrolment was associated with 
greater BMD decline at all anatomical sites (all p<0.001). Age >30 years, Caucasian 
ethnicity, and not being on ART during follow-up were associated with greater decline and 
higher parathyroid hormone associated with a smaller decline in BMD at the femoral neck. 
We found no association between BMD change and exposure to tenofovir disoproxil 
fumarate or protease inhibitors. 
Conclusions: We observed no difference in rate of BMD decline regardless of HIV status 
and in HIV positive subject, having started ART within the previous three months was the 
only factor associated with greater BMD decline at all 3 sites.  
Keywords: bone mineral density, HIV, longitudinal change, antiretroviral therapy 
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Introduction 
Treatment of HIV-infection with antiretroviral therapy (ART) has significantly reduced 
morbidity and mortality [1, 2]. However several disorders associated with chronic HIV-
infection and ART exposure, such as osteoporosis are increasingly emerging with long-term 
survival of treated patients [3]. 
Low bone mineral density (BMD) and osteoporosis are commonly reported across numerous 
cohorts of both men and women with HIV-infection [4-6], with a greater decline in BMD 
with antiretroviral therapy initiation. In several studies, including a number of randomised 
clinical trials, initiation of ART, regardless of the selected regimen, has been found to reduce 
BMD by 2%-6% over the first 2 years of therapy [7-10], with subsequent stabilization [11-
13]. Several factors likely contribute to reduced BMD in HIV-infected patients, including the 
pro-inflammatory effects of chronic HIV-infection, effects of ageing on BMD, genetic 
predisposition, endocrine dysfunction such as menopause, low calcium and vitamin D intake, 
smoking and low body mass index (BMI) [14, 15]. Exposure to the nucleotide reverse 
transcriptase inhibitor tenofovir disoproxil fumarate (TDF), some protease inhibitors (PIs) [7, 
9, 16-18] and pre-ART immunodeficiency [19] have also been implicated in greater BMD 
loss upon ART initiation.  
Bone undergoes continual remodelling mediated by tightly integrated contrasting activity of 
bone resorbing osteoclasts and bone forming osteoblasts. The functional balance and cross-
talk between osteoblasts and osteoclasts is pivotal in regulating bone mass [20]. Circulating 
levels of bone turnover markers (BTM) reflect these underlying processes and can be used to 
indicate changes in either bone resorption or formation. Markers of bone resorption include 
C-terminal cross-linking telopeptide of type 1 collagen (CTX-1) and N-terminal cross-linking 
telopeptide of type 1 collagen (NTX-1) and markers for bone formation include bone-specific 
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alkaline phosphatase (Bone ALP), procollagen type 1 N-propeptide (P1NP) and osteocalcin 
(OC) [21]. When bone resorption exceeds bone formation, a net reduction of bone mass 
results. With initiation of ART in HIV-infection, this balance is impaired, resulting in 
preferential bone resorption and subsequent loss of bone mass [20].  
In cross-sectional analyses, HIV infection and high bone turnover as measured by BTM have 
both been associated with low BMD [1, 22-25], a relationship which was further defined in a 
baseline cross-sectional analysis of the Understanding the Pathology of Bone Disease in HIV 
infected Subjects (HIV UPBEAT) cohort, in which both HIV positive and negative groups 
were compared [22]. Whether such an association is maintained in longitudinal studies 
remains unclear. This study aimed to compare rates of, and factors associated with, change in 
BMD over time between HIV-positive and HIV-negative subjects and to determine HIV-
related predictors of change in BMD.  
Methods  
Population and study design  
The HIV UPBEAT study is a 3 year, single site, prospective observational cohort study that 
enrolled HIV-positive and HIV-negative subjects from similar demographic backgrounds. 
HIV-positive subjects were recruited from the Infectious Disease clinic at the Mater 
Misericordiae University Hospital, Dublin, Ireland, whereas the HIV-negative subjects were 
recruited from the local Dublin area using a range of recruitment strategies. Of note, these 
subjects were recruited from the local community rather than from other hospital-based 
chronic disease clinics. 
 Between February 2011 and July 2012, subjects enrolled into the study had their baseline 
visit and dual x-ray absorptiometry (DXA) scans at femoral neck (FN), total hip (TH) and 
lumbar spine (LS) performed and annually thereafter. All subjects were scanned on a Lunar 
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
    
 
Prodigy-energy X-ray absorptiometry scanner (GE Medical Systems, Madison, Wisconsin, 
USA) utilising Encore software version 12.10 for acquisition and analysis. Dual femur 
(femoral neck, total hip) and lumbar spine scans were obtained using a standardized protocol. 
Short term in vivo variability was 1.12% at femoral neck of hip. 
Demographic and treatment history information were collected at study entry. Plasma and 
serum samples were collected at study entry and annually until end of study (following an 8-
hour overnight fast, water permitted). Fasting blood tests including full blood count, urea and 
electrolytes, liver function tests (bilirubin, alkaline phosphatase (ALP), alanine 
aminotransferase (ALT), gamma-glutamyl transferase (GGT), albumin), bone profile 
(corrected calcium, phosphate), lipid profile, glucose, thyroid function tests, were analysed by 
routine methodologies. HIV and hepatitis B and C serology were assessed in the HIV-
negative group. Intact parathyroid hormone (PTH) was measured using sandwich 
immunoassay with chemi-luminescent detection (Siemans, Centaur, Erlangen, Germany); 
Serum and plasma samples were stored at -80 degrees Celsius. Serum 25(OH)D was 
measured by radio-immunoassay (Diasorin, Saluggia, Italy). After baseline visit completion, 
stored plasma samples were utilised for bone biomarker analyses. CTX-1, OC (N-mid OC[1-
43]) and P1NP were measured using electrochemi-luminescence immunoassays (Roche 
Diagnostics, Basel, Switzerland). Coefficients of variation for all assays were within 
acceptable limits. CD4+ T-cell count and HIV-1 RNA levels were measured as part of 
routine clinical care concurrently with other measures.  
BMD at femoral neck, total hip and lumbar spine were measured in grams per centimetre 
squared (g/cm2). A detailed description of the HIV UPBEAT study, BMD assessments and 
laboratory methods have been described previously [22]. The present analysis was restricted 
only to subjects with at least two longitudinal BMD measurements. All participants gave 
written, informed consent and approval was granted by the local ethics committee. 
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Statistical Analysis  
Between-group differences in demographic and clinical variables at baseline were assessed 
using the Mann-Whitney U test for continuous variables and the Chi-squared test for 
categorical variables. The study primary-endpoint was the difference in rate of change in 
BMD between the HIV-positive and HIV-negative groups at FN, TH and LS over 3 years. To 
address this primary-endpoint, we compared BMD values (log transformed to stabilize the 
variance and linearize changes over time) at baseline and over time between the HIV-positive 
and HIV-negative group’s at all three anatomical sites using mixed effects regression models. 
The mixed models included patient-specific random intercepts and random slopes over time 
to allow for heterogeneity in patients’ initial BMD levels and subsequent changes. The initial 
model included time (calculated from the date of the first assessment and measured in years), 
HIV status and the interaction between time and HIV status as independent variables. This 
allowed us to investigate the overall rate of change of BMD in the full sample, and to 
formally assess whether this change differed significantly between the HIV-positive and 
HIV-negative groups. 
We next investigated whether changes in BMD over follow-up were associated with 
traditional risk factors for low BMD, including age (≤30; >30 years), sex (male, female), 
ethnicity (Caucasian, non-Caucasian), smoking status (current smoker, noncurrent smoker) 
and BMI, through the inclusion of additional interaction terms between each covariate and 
time. Factors that were not significantly associated with the absolute BMD or its change over 
time (p>0.05) were then removed from this model.  
We next performed a subgroup analysis on the HIV-positive group only, to identify HIV-
related predictors of absolute change in BMD at FN, TH and LS. Due to the very large 
number of potential covariates, we firstly performed an exploratory analysis using baseline 
BMD values and a naïve linear regression (with the estimated BMD slope as the outcome 
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variable) to select the appropriate form for each covariate. In the exploratory analysis, 
variables that exhibited inconsistent directions of associations with BMD across the three 
anatomical sites were not considered for further analysis (assuming a lack of biological 
plausibility and likelihood of type I errors). In addition to the demographic variables and 
BMI, these exploratory analyses also considered the following variables: laboratory variables 
(alkaline phosphatase, phosphate, parathyroid hormone (PTH), 25-hydroxy-vitamin D 
(25(OH)D, bone turnover marker variables (OC, CTX-1 and P1NP) and HIV-specific 
variables (HIV acquisition risk (injection drug use (IDU); non-IDU), current TDF use, 
current PI use, current non-nucleoside reverse transcriptase inhibitor (NNRTI) use, ART 
status (on continuous ART during follow-up and having started ART >3 months prior to 
study enrolment; having started ART at sometime between <3 months prior to or after study 
enrolment; not on ART). Mixed effects models were then used to select variables to be 
included in the multivariable analyses based on their potential effect on baseline BMD levels 
or absolute decline in BMD. 
Multivariable mixed effects models were then constructed to include relevant variables from 
the exploratory analysis, with covariates considered for inclusion in the following order: 
demographics, BMI, laboratory variables, bone turnover markers and HIV-specific variables. 
On adding each set of variables into the model, a backward selection approach was used to 
remove any variables that did not remain independently associated with baseline BMD level 
and/or the absolute change in BMD. Once a parsimonious model had been achieved, we then 
proceeded to add the next set of variables. Using a similar approach, we examined the 
additional effects of current and nadir CD4+ T-cell counts and baseline HIV RNA (≤40 
copies/ml vs >40 copies/ml) on absolute change in BMD in a sub-group of subjects either on 
continuous ART or having started ART >3 or <3 months prior to or after study enrolment. 
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For interpretation, all model estimates were back transformed. All analyses were conducted 
using STATA 13.1 (College Station, Texas). 
Results 
474 enrolled subjects (of whom 210 were HIV-positive) completed the baseline study visit 
[22]. The longitudinal analyses included 384 subjects (176 HIV-positive) with at least two 
BMD measurements. There were no significant differences in demographic characteristics, 
laboratory variables and bone-turnover markers between the 474 enrolled subjects and the 
384 subjects with at least two follow-up BMD measurements (data not shown).  
Of the 384 subjects, 120 (57 HIV-positive) contributed two and 264 (119 HIV-positive) 
contributed three BMD annual measurements. Subjects were followed up for median 
(interquartile range (IQR)) duration of 103 (88-177) weeks. 
Baseline characteristics of the HIV-positive and HIV-negative groups included in the analysis 
are presented in Table 1. Compared to the HIV-negative group, those with HIV were younger 
and more likely to be male, of African ethnicity, to currently smoke and to be hepatitis C 
antibody positive. There were no significant differences in median BMI at baseline between 
the HIV-positive and HIV-negative groups. 
Laboratory variables and bone turnover markers 
Baseline alkaline phosphatase, corrected calcium, parathyroid hormone and bone biomarkers; 
OC, P1NP, CTX-1 were significantly higher in the HIV-positive group than in the HIV 
negative group. (Table 1) as previously reported [22]. There were no significant differences 
in 25(OH) D between the HIV-positive and HIV-negative groups. 
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Baseline differences and differences in absolute change in bone mineral density  
Compared to the HIV-negative group, the HIV-positive group had significantly lower 
baseline BMD at the FN (median (IQR) 1.024 (0.927-1.135) g/cm2 vs 1.055 (0.964-1.159) 
g/cm2; p=0.003), TH (1.061 (0.942-1.157) g/cm2 vs 1.107 (1.000-1.196) g/cm2; p=0.003) and 
LS (1.164 (1.061-1.304) g/cm2 vs 1.238 (1.135-1.348) g/cm2; p=0.001). 
In general BMD declined at all three anatomical sites within the overall cohort and in both 
sub-groups. From the mixed effects regression models, the decline in BMD in the overall 
cohort was significant at all three anatomical sites (-0.0046 g/cm2/yr at FN,-0.0041 g/cm2/yr 
at TH and -0.0033 g/cm2/yr at LS, all p<0.001). In the HIV-positive group, BMD 
significantly declined at FN (-0.0063 g/cm2/yr; p=0.001), TH (-0.0044 g/cm2/yr; p<0.001) but 
not at LS (-0.0024 g/cm2/yr; p=0.25). Similarly, in the HIV-negative group, BMD 
significantly declined at FN (-0.0028 g/cm2/yr; p=0.023) and TH (-0.0036 g/cm2/yr; p<0.001) 
but not at LS (-0.0041 g/cm2/yr; p=0.08). Despite the within-group changes in BMD, there 
were no significant between-group differences in the rate of absolute change in BMD at FN, 
TH or LS (Figure 1). Further adjustment for age, gender, ethnicity, smoking status and BMI 
in a multivariable mixed effects regression analysis minimally affected the estimated rates of 
BMD decline (Table 2). 
HIV-specific analysis 
Predictors of absolute change in BMD in HIV-infected subjects 
In the unadjusted mixed effects regression models (Table 3), having started ART<3 months 
prior to or after study enrolment was significantly associated with greater subsequent BMD 
decline at FN, TH and LS, while not being on ART during study follow-up was also 
significantly associated with greater subsequent BMD decline but only at FN. Interestingly, 
current PI use was significantly associated with a lesser decline in BMD but only at FN. 
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There was no association between change in BMD and current or cumulative exposure to 
tenofovir disoproxil fumarate (TDF). 
Analysis of circulating factors associated with bone function revealed inconsistent results. 
Higher baseline corrected calcium was significantly associated with reduced subsequent 
BMD decline but only at LS, while, surprisingly, a higher baseline PTH was significantly 
associated with reduced subsequent decline in BMD at FN and TH but not LS. Higher 
baseline ALP was significantly associated with reduced subsequent BMD decline at FN and 
LS but not TH, while a higher baseline P1NP was significantly associated with reduced 
subsequent decline in BMD at FN, TH and LS, and higher baseline OC and CTX-1 were 
significantly associated with a reduced decline in BMD but only at FN. 
In multivariable mixed effects models within the HIV-positive group (Table 4), age over 30 
years and Caucasian ethnicity were independently associated with a greater subsequent 
decline in BMD at FN of -0.013 g/cm2/year (p=0.02) and -0.011 g/cm2/year (p=0.006), 
respectively. Compared to being on continuous ART or having started ART >3 months prior 
to study enrolment, having started ART<3 months prior to or after study enrolment and not 
being on ART during study follow-up were independently associated with a greater 
subsequent BMD decline at FN of -0.016 g/cm2/year (p=0.002) and of -0.019 g/cm2/year 
(p=0.012), respectively, while the effect of recent ART initiation was also seen at TH and LS 
of -0.014 g/cm2/year and -0.025 g/cm2/year, respectively (all p<0.001). In addition, 
surprisingly, a one pmol/L increase in baseline PTH was independently associated with a 
reduced subsequent BMD decline at FN of 0.0017 g/cm2/year (p=0.007). In an analysis 
restricted to subjects on stable ART (>12 months), to exclude the possibility that the effects 
of PTH on BMD decline might be affected by measurement of individuals who started ART 
after or just prior to baseline, PTH remained independently associated with a smaller decline 
in BMD at femoral neck (data not shown).  
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In a further sub-group analysis of subjects either on continuous ART or having started ART 
>3 months prior to or after study enrolment and those having started ART <3 months prior to 
or after study enrolment, to assess the independent effects of baseline CD4+ T-cell count and 
HIV RNA<40 copies/ml on absolute change in BMD, higher baseline CD4+ T-cell count 
remained independently associated with higher baseline BMD at FN (+1.00 g/cm2, p=0.006) 
and TH (+1.00 g/cm2, p=0.005) but not with absolute change in BMD.  
 
Discussion 
In this 3 year, prospective study of subjects with and without HIV, although BMD declined in 
the whole cohort at all 3 anatomical sites, there was no evidence of between-group 
differences in the rate of BMD decline over time between the HIV-positive and HIV-negative 
groups in analyses adjusted for traditional risk factors for low BMD including age, gender, 
ethnicity, smoking and BMI. In an HIV-specific sub-analysis, having started ART within the 
previous three months was the only factor associated with greater BMD decline at all 3 sites, 
with no evidence to support an effect of ART itself, or specific components such as TDF or 
PI, in accelerating bone loss. 
That the rate of BMD decline was similar in both those with and without HIV infection is 
consistent with similar observations reported in other longitudinal studies with a comparative 
HIV-negative group, with some specific study population composition differences. Dolan et 
al [5] and Sharma et al  [4] reported that rates of change in BMD were not different between 
HIV-infected women and healthy controls at the LS, FN, or TH. Yin et al. found no 
difference in the rate of bone loss at LS and FN between premenopausal HIV-infected and 
uninfected women [26]. Bolland et al [12] and Sharma et al [3] found no evidence of 
between-group differences in the rate of BMD loss at LS, TH or FN between highly active 
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antiretroviral therapy (HAART) treated HIV-infected men and HIV-negative controls. In 
these BMD longitudinal studies among men or women with a comparative HIV-negative 
group, the duration of follow-up ranged from 1.5 [3, 4] to 6 years [27], with sample size 
ranging between 81 [27] and 464 [4]. This present study of medium duration of follow-up 
and relatively large sample size further reaffirms this observation of lack of a between-group 
difference in the rate of BMD decline, with the advantage of including a more heterogeneous, 
European-based population with a control group derived from a similar demographic as the 
HIV positive cohort. 
The effect of ART on BMD in people living with HIV has been well defined in prospective, 
randomized clinical trials with much of the change in BMD with ART observed within the 
first year after ART initiation [9, 10, 28]. Our finding that subjects recently started on ART 
had greater decline in BMD is consistent with these data. Furthermore, no evidence for 
greater BMD decline once on established ART for >3 months was observed. This is similar 
to observations from a US cohort in younger men [11] and cohorts of men or premenopausal 
women in which the majority of subjects treated with effective ART at baseline had stable or 
increasing BMD during follow-up [6].  
Similar to other analyses, such as that from the SMART study, an international randomized 
trial comparing continuous with intermittent antiretroviral treatment [29], we did not find 
evidence for greater BMD decline in those with exposure to specific antiretrovirals such as 
TDF or PI. This is also in agreement with Nolan et al [13], who did not find evidence of 
greater BMD decline. While the association between initiation of ART containing TDF and 
larger reductions in BMD has been demonstrated in several randomized trials [30-32], the 
role of PIs has been contradictory, ranging from an increase [11, 13] to a decrease [17, 33] in 
BMD in ART-experienced or ART-naïve subjects receiving ART regimens that included PI. 
The lack of association in our study could potentially be explained by the fact that the effects 
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of individual drugs may have been too weak to be identified in the presence of other factors 
more strongly influencing BMD change, or more likely that once ART is initiated for > 3 
months, there is no additional, clinically relevant impact from specific antiretroviral drugs on 
progressive BMD loss.  
The observation of greater BMD decline in those aged above 30 years and in those of 
Caucasian ethnicity is not surprising, as these are well-established risk factors for low BMD 
in many studies. However, this analysis also observed associations between higher PTH 
levels and a slower rate of BMD decline that runs contrary to a previous randomised trial 
comparing an NNRTI versus NRTI-containing ART regimen, both used in combination with 
PI, in ART-naïve men, which demonstrated a correlation between increasing PTH levels and 
a greater reduction in BMD at LS [28]. However in that study, in the NNRTI study group that 
experienced the greatest PTH increase, BMD loss was less compared to the NRTI group, 
suggesting that PTH may not explain this greater BMD loss. Although increased PTH levels 
have been associated with low BMD in HIV, our study suggests little evidence for a 
significant role.  
Within the baseline analysis of this cohort, significantly higher bone turnover markers were 
observed in those with HIV and were associated with lower BMD [22]. Higher bone turnover 
in HIV is well described, with temporary uncoupling of bone turnover that coincides with 
initiation of antiretroviral therapy resulting in a catabolic window during which BMD loss 
occurs [18]. In this study, bone turnover markers were not associated with BMD decline in 
adjusted analyses, bringing into question their role in driving ongoing change in BMD 
beyond the period of ART initiation. Although there are few prospective data other than the 
present study describing sustained high bone turnover states and the consequence on BMD in 
those with HIV, based on our data, we would speculate that if bone turnover is coupled, even 
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at an overall higher level in those with HIV, that progressive loss of bone may not be 
observed. 
There are several limitations to our study. At study enrolment, a majority of the HIV-positive 
subjects had already been on ART for extended periods of time, limiting our ability to 
determine the impact of ART initiation on BMD loss. The majority of the HIV-positive 
subjects were on TDF-including regimens (83%), limiting our ability to determine whether 
associations between TDF and BMD loss were TDF-specific or reflecting a class-wide 
association. Although we were able to detect statistically relevant declines in BMD over time, 
the absolute changes were relatively small and the limited follow-up in our cohort prevents us 
from determining if these declines will continue and whether they will result in clinically 
relevant BMD loss over a longer period of follow-up. Our cohort was also of a relatively 
young age (average age 42 years) and hence at low overall risk of BMD loss, resulting in 
small absolute BMD changes, with potentially larger changes expected in an older 
population. Despite these limitations, that our study is relatively large in its makeup and 
includes an appropriate control group enables important and clinically relevant observations 
to be made that significantly contribute to our understanding of long-term changes in BMD in 
people living with HIV.  
In conclusion, our findings suggest that although those with HIV have low BMD, there is no 
difference in the rate of BMD decline between HIV-positive and HIV-negative subjects over 
time, with recent ART initiation a major factor determining a greater decline in BMD and a 
relatively stability of BMD over time once on established ART. 
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Table 1: Characteristics of HIV-positive and HIV-negative subjects included in analysis 
 HIV-positive 
(n=176) 
HIV-negative 
(n=208) 
P-value 
Age (median (IQR) years) 39 (34-46) 43 (35-50) 0.04 
Male gender, n (%)  107 (61%) 95 (46%) 0.003 
African ethnicity, n (%) 68 (39%) 37 (18%) <0.001 
Hepatitis C Ab positive, n (%) 23 (13%) 2 (1%) <0.001 
Hepatitis B sAg positive, n (%) 4 (2%) 1 (0.5%) 0.18 
Current smoker, n (%) 60 (34%) 31 (15%) <0.001 
BMI (median (IQR) kg/m2) 26 (23-30) 27 (24-30) 0.07 
Education, n (%)    
  Third level 88 (50%) 138 (66%) 0.002 
  Primary/Secondary level 77 (44%) 66 (32%)  
  Undisclosed 11 (6%) 4 (2%)  
Any history of fractures, n (%) 53 (30%) 50 (24%) 0.18 
HIV transmission risk group, n 
(%) 
 -  
  Heterosexual  90 (51%) -  
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  Homosexual 55 (31%) -  
  Injection drug user 29 (17%) -  
  Other 2(1%) -  
Current ART, n (%) 155 (88%) -  
Total ART exposure (median 
(IQR) years) 
2.9 (0.7-5.4) -  
  TDF, n (%) 128 (83%) -  
  exposure (median (IQR) 
years) 
1.3 (0.1-2.9) -  
  PI, n (%) 73 (47%) -  
  exposure (median (IQR) 
years) 
0.3 (0.0-2.6) -  
  NNRTI, n (%) 77 (50%) -  
  exposure (median (IQR) 
years) 
0.2 (0.0-2.6) -  
HIV RNA ≤40 cp/ml, n (%) 121 (78%) -  
Nadir CD4+ T-cell (median 
(IQR) cell/mm3) 
218 (134-309) -  
Current CD4+ T-cell (median 
(IQR) cell/mm3) 
508 (370-650) -  
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
    
 
Current CD8+ T-cell (median 
(IQR) cell/mm3) 
787 (596-1085) -  
Time since HIV diagnosis 
(median (IQR) years) 
4.0 (2.0-9.0) -  
Laboratory variables    
Albumin (median (IQR) g/L) 39 (37-42) 41 (40-43) <0.001 
ALT (median (IQR) IU/L) 28 (20-36) 26 (19-36) 0.04 
ALP (median (IQR) IU/L) 79 (65-101) 63 (53-74) <0.001 
Corrected calcium (median 
(IQR) mmol/L) 
2.31 (2.25-2.36) 2.27 (2.22-2.31) <0.001 
Phosphate (median (IQR) 
mmol/L) 
1.06 (0.95-1.17) 1.03 (0.93-1.13) 0.13 
25 (OH) D (median (IQR) 
nmol/L) 
50.5 (31.0-70.5) 53.0 (37.0-75.0) 0.33 
PTH (median (IQR) pmol/L) 5.9 (4.6-8.4) 5.3 (4.2-6.8) 0.001 
Free T4 (median (IQR) 
pmol/L) 
13.0 (11.9-14.1) 13.2 (12.2-14.4) 0.13 
TSH (median (IQR) mIU/l) 1.71 (1.14-2.42) 1.53 (1.11-2.20) 0.12 
Haemoglobin (median (IQR) 
g/dL) 
13.9 (12.6-15.0) 13.9 (12.7-14.7) 0.69 
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Platelets (median (IQR) 
x109/L) 
226 (195-279) 256 (215-288) 0.005 
Bone turnover markers    
OC (median (IQR) ug/L) 21.5 (15.8-28.4) 17.2 (16.7-29.9) <0.001 
CTX-1 (median (IQR) ug/L) 0.489 (0.306-0.616) 0.344 (0.261-0.465) <0.001 
P1NP (median (IQR) ug/L) 49.2 (35.7-65.7) 37.0 (28.5-46.1) <0.001 
BMI-body mass index, Ab-antibody, sAg-surface antigen, TDF-tenofovir disoproxil 
fumarate, PI-protease inhibitor, NRTI-nucleoside reverse transcriptase, NNRTI-non-
nucleoside reverse transcriptase inhibitor, ALT-alanine aminotransferase, ALP-alkaline 
phosphatase, 25 (OH)D-25-hydroxy-vitamin D, PTH-parathyroid hormone, TSH-thyroid-
stimulating hormone, OC-osteocalcin, CTX-1-C-terminal cross-linking telopeptide of type-1 
collagen, P1NP-procollagen type-1 amino-propeptide 
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Table 2 Results from unadjusted and adjusted mixed effects regression models for the between-group difference in absolute change in BMD between 
HIV-positive and HIV-negative subjects 
Unadjusted mixed effects regression model   
  
Between group 
difference in BMD 
at FN (g/cm2/yr) 
95% CI 
P-
value 
Between group 
difference in 
BMD at TH 
(g/cm2/yr) 
95% CI P-value 
Between group 
difference in 
BMD at LS 
(g/cm2/yr) 
95% CI P-value 
HIV-positive 
vs HIV-
negative  
-0.0035 -0.0078; 0.00078 0.11 -0.0008 -0.0038; 0.0026 0.71 0.0017 -0.0036; 0.0073 0.51 
*Adjusted mixed effects regression model 
 
HIV-positive 
vs HIV-
negative 
-0.0038 -0.0081; 0.00046 0.08 -0.001 -0.0038; 0.0025 0.69 0.0018 -0.0036; 0.0073 0.51 
*adjusted for age, gender, ethnicity, smoking status, educational level and body mass index (BMI) 
 FN-femoral neck, TH-total hip, LS-lumbar spine, CI-confidence interval 
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Table 3: Results from unadjusted mixed effects regression models results for factors associated with BMD slope at FN, TH and LS in HIV-positive subject 
aEffect on absolute  
change in FN BMD 95% CI P-value 
aEffect on absolute  
change in TH 
BMD 95% CI P-value 
aEffect on absolute  
change in LS BMD 95% CI P-value 
Demographic variables          
Female gender vs Male gender 0.0016 -0.0058; 0.0091 0.67 0.0013 -0.0039; .0066 0.62 -0.0041 -0.013; 0.0044 0.35 
Age>30 vs Age<30 -0.0082 -0.019; 0.0028 0.15 -0.0051 -0.013; 0.0027 0.20 -0.0025 -0.015; 0.010 0.70 
Caucasian vs non-Caucasian -0.0033 -0.011; 0.0041 0.39 0.0018 -0.0034; 0.0070 0.50 -0.0035 -0.012; 0.0050 0.42 
Unknown vs 1st/2nd level 
education 
0.0013 -0.014; 0.017 0.87 -0.0017 -0.013; 0.0096 0.77 -0.0053 -0.024; 0.013 0.58 
3rd vs 1st/2nd level education -0.0053 -0.013; 0.0021 0.16 -0.0021 -0.0073; 0.0031 0.44 -0.00064 -0.0092; 0.0079 0.88 
IDU vs non-IDU HIV acquisition 0.0026 -0.0072; 0.012 0.60 -0.0033 -0.010; 0.0036 0.35 -0.0026 -0.014; 0.0087 0.66 
BMI (per 5kg/m2 higher) 0.00086 -0.0023; 0.0040 0.59 0.00090 -0.0013; 0.0031 0.43 0.00030 -0.0034; 0.0040 0.87 
Baseline laboratory variables          
ALP (per 5IU/L increment ) 0.00075 0.000096; 0.0014 0.03 0.00038 -0.000089; 0.00084 0.11 0.00078 0.000045; 0.0015 0.04 
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Calcium (per mmol/L increment) -0.012 -0.051; 0.026 0.53 -0.011 -0.038; 0.016 0.44 -0.047 -0.091; -0.0040 0.03 
Phosphate (per mmol/L 
increment) 
-0.0061 -0.026; 0.014 0.55 -0.0031 -0.017; 0.011 0.67 -0.013 -0.036; 0.0097 0.26 
25 (OH) D (per 5 nmol/L 
increment) 
-0.00019 -0.00075; 0.00036 0.50 -0.00016 -0.00054; 0.00022 0.40 -0.00012 -0.00075; 0.0005 0.69 
PTH (per pmol/L increment) 0.0014 0.00028; 0.0025 0.01 0.0011 0.00035; 0.0019 0.004 0.0012 -0.00004; 0.0025 0.06 
Baseline bone turnover 
markers 
         
OC (per ug/L higher) 0.0019 0.00022; 0.0037 0.03 0.00073 -0.00049; 0.0019 0.24 0.0012 -0.00085; 0.0032 0.26 
CTX-1 (per 0.100 ug/L 
increment) 
0.0017 0.000048; 0.0034 0.04 0.00075 -0.00044; 0.0019 0.22 0.00064 -0.0013; 0.0026 0.52 
P1NP (per 10ug/L increase) 0.0019 0.00036; 0.0034 0.02 0.0012 0.00016; 0.0023 0.024 0.0021 0.00035; 0.0038 0.02 
HIV-specific variables          
Started ART<3 months pre/after 
enrolment vs continuous follow-
up ART 
-0.019 -0.029; -0.0097 <0.001 -0.016 -0.023; -0.0094 <0.001 -0.026 -0.037; -0.015 <0.001 
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
    
 
aEffects on change represents the interaction between the individual variable with time in the mixed effects model  
 IDU-injection drug use, BMI-body mass index, ALT-alanine aminotransferase, ALP-alkaline phosphatase, 25 (OH) D-25-hydroxy-vitamin D, PTH-parathyroid hormone, 
OC-osteocalcin, CTX-1-C-terminal cross-linking telopeptide of type-1 collagen, P1NP-procollagen type-1 amino-propeptide, TDF-tenofovir disoproxil fumarate, PI-protease 
inhibitor, NRTI-nucleoside reverse transcriptase, NNRTI-non-nucleoside reverse transcriptase inhibitor 
 
 
Not on ART vs continuous 
follow-up ART 
-0.021 -0.035; -0.0059 0.006 -0.0029 -0.013; 0.0075 0.58 -0.0070 -0.024; 0.010 0.43 
Current TDF vs no current TDF 
use 
0.0069 -0.0013; 0.015 0.10 0.0028 -0.003; 0.0087 0.34 -0.0049 -0.015; 0.0046 0.31 
Current PI vs no current PI use 0.0074 0.000088; 0.015 0.05 0.00067 -0.0045; 0.0058 0.80 0.0039 -0.0045; 0.012 0.37 
Current NNRTI vs no current 
NNRTI use 
-0.00058 -0.0079; 0.0067 0.88 0.0015 -0.0036; 0.0066 0.57 -0.0020 -0.010; 0.0064 0.64 
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Table 4: Results from multivariable mixed effects regression models for factors 
independently associated with absolute change in BMD at FN, TH and LS BMD in HIV-
positive subjects 
 FN BMD* TH BMD‡ LS BMD† 
 aEffe
ct on 
FN 
slope 
95% CI P aEffe
ct on 
TH 
slope 
95% CI P aEffe
ct on 
LS 
slope 
95% 
CI 
P 
Age >30 vs  <30 
years 
-
0.013 
-0.02; -
0.002 
0.
02 
n/a   n/a   
Caucasian vs non-
Caucasian 
Ethnicity 
-
0.011 
-0.02; -
0.003 
0.
00
6 
n/a   n/a   
PTH (per 1 pmol/L) 0.001
7 
0.0005; 
0.003 
0.
00
7 
0.000
6 
-0.0002; 
0.001 
0.1
2 
n/a   
ART< 3months 
pre/after study 
enrolment vs 
continuous  ART 
-
0.016 
-0.026; -
0.006 
0.
00
2 
-
0.014 
-0.02; -
0.007 
<0.
001 
-
0.025 
-0.04; 
-0.01 
<0.
001 
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Not on ART vs 
continuous ART 
-
0.019 
-0.03; -
0.004 
0.
01 
-
0.002
4 
-0.01; 
0.008 
0.6
5 
-
0.006
2 
-0.02; 
0.01 
0.4
8 
aEffects on absolute change represents the interaction between the individual variable with time 
in the mixed effects model  
,PTH-parathyroid hormone 
*Model adjusted for baseline variables: gender, education level, BMI, ALP, 25(OH) D and CTX-
1 
‡Model adjusted for gender, ethnicity, BMI, baseline ALP, PTH and CTX-1 
†Model adjusted for ethnicity, BMI, baseline ALP, and CTX-1  
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